Maravai LifeSciences Holdings Inc. Class A Common Stock vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $18.13 (market cap $70.22B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 71.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.36% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 3 Days on average.
| MRVI | NWG | |
|---|---|---|
Market Cap | $977.37M | $70.22B |
Volume | 2,742,564 | 3,419,107 |
Sector | Health | Financials |
52-Week High | $9.00 | $19.42 |
52-Week Low | $2.83 | $13.89 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $1.08B | $143.28B |
Dividend Yield | — | 5.36% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NatWest Group (NWG) trades at $17.65, up 2.38% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a low P/E of 8.94 and robust profitability with a net income margin of 36.24%. Recent earnings have consistently beaten expectations, and analyst sentiment is positive, with a 'Moderate Buy' consensus. The company has upgraded its 2026 guidance and accelerated share buybacks, supported by healthy revenue growth and improving deposit margins.
The outlook for NWG is favorable, driven by earnings momentum and supportive analyst coverage, though risks include negative cash flow trends and potential regulatory scrutiny. The stock presents a value opportunity given its attractive valuation and strong return on equity, but investors should monitor execution on profitability targets and macroeconomic impacts on the banking sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →